Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 601 AL 615

Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis

Shim GH, Lau ECY, Huynh ALH, Lu CY, Tan ECK.

Ageing Res Rev. 2026 Jan;114:102981. doi: 10.1016/j.arr.2025.102981. Epub 2025 Dec 4.

Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review

Shami R, El Majzoub R, Ismail A, Kotaich J, Kassem M, Safadieh G, Fayyad-Kazan M, Chahine B.

Neurodegener Dis Manag. 2026 Apr;16(2):239-251. doi: 10.1080/17582024.2025.2562776. Epub 2025 Sep 24.

Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: Two case reports and systematic review of reported cases

Villarejo Galende A, González-Sánchez M, Hilario A, Llamas-Velasco S, Morenas-Rodríguez E, Muñoz-García MI, Ramos-González A, Pérez-Martínez DA, Blanco-Palmero VA.

J Alzheimers Dis. 2026 Feb;109(3):1099-1116. doi: 10.1177/13872877251404505. Epub 2025 Dec 12.

Anthocyanins in the treatment of Alzheimer's disease: a systematic review and meta-analysis of animal studies

Chen YN, Xiong ZE, Wen X, He SJ, Zhang XL, Zhang R, Wang T, Zou J.

Nutr Neurosci. 2026 May;29(5):595-612. doi: 10.1080/1028415X.2025.2578641. Epub 2025 Oct 30.

Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension

Nakamura Y, Kurokawa T, Terashima S, Nishimura A.

J Alzheimers Dis. 2026 Jan;109(2):1007-1019. doi: 10.1177/13872877251401601. Epub 2025 Dec 9.

Efficacy and Safety of Gantenerumab in Patients With Alzheimer Disease: A Systematic Review and Meta-analysis

Alla D, Malireddi A, Ramsundar R, Shah D, Alla SSM, Das A, Andanappa A, Emmanuel NW, Siddiqui S, Marepalli NR, Dugyala RR, Kolte R.

Clin Neuropharmacol. 2026 Jan-Feb 01;49(1):4-10. doi: 10.1097/WNF.0000000000000661. Epub 2025 Nov 24.

Initial Real-World Evidence for Lecanemab in the United States

Brixner DI, Zhao C, Toyosaki H, Frech FH, Rosenbloom MH.

Drugs Aging. 2026 Jan;43(1):69-76. doi: 10.1007/s40266-025-01261-x. Epub 2025 Oct 29.

The effects of Lithium on Beta-amyloid deposition and tau phosphorylation: A systematic review

Xiao K, Sayed H, Xing J, Zhang XY, Ai J, Kirichek E, Le GH, Wong S, Valentino K, Teopiz KM, Vinberg M, Rosenblat JD, Lo HKY, Zhang MC, McIntyre RS.

J Affect Disord. 2026 Feb 15;395(Pt A):120721. doi: 10.1016/j.jad.2025.120721. Epub 2025 Nov 17.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial

Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C.

Nat Med. 2026 Jan;32(1):353-361. doi: 10.1038/s41591-025-04106-7. Epub 2025 Dec 1.

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Zimmer JA, Sims JR, Evans CD, Nery ESM, Wang H, Wessels AM, Tronchin G, Sato S, Raket LL, Andersen SW, Sapin C, Paget MA, Gueorguieva I, Ardayfio P, Khanna R, Brooks DA, Matthews BR, Mintun MA; Alzheimer’s Disease Neuroimaging Initiative.

J Prev Alzheimers Dis. 2026 Feb;13(2):100446. doi: 10.1016/j.tjpad.2025.100446. Epub 2025 Dec 1.

Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies

Baviskar PS, Mahajan HS.

Ageing Res Rev. 2026 Jan;114:102990. doi: 10.1016/j.arr.2025.102990. Epub 2025 Dec 10.

An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease (2021-present)

Begines P, Fernández-Bolaños JG, López Ó.

Expert Opin Ther Pat. 2026 Feb;36(2):159-190. doi: 10.1080/13543776.2025.2602702. Epub 2025 Dec 23.

Intranasal insulin for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials

Silva AMP, Gonçalves OR, Tudella GCN, Nascimento MVS, Pereira MAOM, Nantes LAO, Fernandes JVA, Quiroga DG, Lima DVS Jr, Franco ES, Maia MBS.

Rev Neurol (Paris). 2026 Jan-Feb;182(1-2):36-48. doi: 10.1016/j.neurol.2025.11.005. Epub 2025 Dec 22.

Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis

Kandeel M, Mahmoud M.

J Alzheimers Dis. 2026 Feb;109(3):1089-1098. doi: 10.1177/13872877251404500. Epub 2025 Dec 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias